The Food and Drug Administration (FDA) has approved AstraZeneca and Sanofi's shot, called nirsevimab, which protects infants and toddlers against respiratory syncytial virus (RSV). This is the first shot approved by the FDA to protect all infants against RSV, regardless of their health condition. Nirsevimab is administered as a single injection, unlike the currently available shot, palivizumab, which is given monthly throughout the RSV season. RSV is a leading cause of hospitalization among babies in the US and a major public health threat. Nirsevimab was found to be effective in preventing lower respiratory tract infections and hospitalization without any identified safety concerns.

The post Fda Approves Astrazeneca, Sanofi shot that protects infants and toddlers against RSV appeared first on Balanced News Summary.